Insights & Discussion
Carrageenan, a common food additive, has dual aspects, being both useful in drug delivery and food printing, while potentially harmful via inducing intestinal inflammatory conditions.
This study investigates the dual roles of carrageenan, a naturally occurring polysaccharide. It is used in creating edible films and encapsulating drugs, and has potential uses in food printing. Moreover, it can regulate the composition of intestinal microflora, including promoting the increase of Bifidobacterium bacteria. The research shines a light on the harmful side of carrageenan as well by focusing on its interactive effects with intestinal microflora, mucous barrier, and proinflammatory pathways.
The study reveals that carrageenan negatively alters intestinal microflora, triggering a breakdown of the mucus barrier, leading to an inflammatory response. This response occurs due to activation of the pro-inflammatory nuclear factor kappa-light-chain-enhancer pathway in the epithelial cells, likely via the mechanism of TLR4 receptor activation, alteration in macrophage activity, production of proinflammatory cytokines, and activation of innate immune pathways. Carrageenan's influence also led to increased levels of Bacteroidetes bacteria, alongside reducing short-chain fatty acid-producing bacteria, ultimately damaging the integrity of the intestinal membrane and reducing the mucin layer. The study finds that those with intestinal inflammation disorders, like Crohn's disease and ulcerative colitis, are particularly vulnerable to these harmful effects.
Discover Related Insights
Carrageenan, a common food additive, potentially exacerbates Inflammatory Bowel Disease (IBD) symptoms by altering gut microbiota, inducing intestinal permeability, and triggering inflammation.
2024 Nutrients Carrageenan in the Diet: Friend or Foe for Inflammatory Bowel Disease? Kimilu N, Gładyś-Cieszyńska K, Pieszko M, Mańkowska-Wierzbicka D, Folwarski M
Carrageenan Inflammatory Bowel Disease
The study involved a comprehensive literature review, where the researchers carried out an in-depth analysis of past studies evaluating carrageenan's impact on gut health, particularly in relation to Inflammatory Bowel Disease (IBD). Using predefined search terms, they scoured medical and scientific databases, MEDLINE and SCOPUS. They considered research focusing on carrageenan's effect on the gut microbiota, intestinal permeability, inflammatory processes, its relationship with cancer, and its role as a food additive in the context of autoimmune diseases.
The review divulged that degraded carrageenan, as used in animal studies, appeared to promote intestinal ulceration and inflammation, suggesting a potential risk in exacerbating IBD. Additionally, carrageenan also appeared to disrupt gut microbiota, reducing bacterial diversity therein, and increased intestinal permeability, which in turn could possibly contribute to 'leaky gut' syndrome. Interestingly, some studies suggested a possible anti-cancer effect, since carrageenan might inhibit the growth of cancer cells by affecting cell cycle progression. Besides, the additive seemed to elevate glucose intolerance and insulin resistance.
Carrageenan intake can lead to an earlier relapse in patients with ulcerative colitis who are in remission.
2017 Nutrition and Healthy Aging A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity Bhattacharyya S, Shumard T, Xie H, Dodda A, Varady KA, Feferman L, et al.
Randomised Controlled Trial Carrageenan Ulcerative Colitis
In the methods employed, a clinical trial was carried out to determine if ulcerative colitis patients could avoid or defer relapse by following a diet devoid of carrageenan. Participants were educated about the no-carrageenan diet, and then divided into two groups - one receiving capsules containing carrageenan and the other receiving placebo capsules. The amount of carrageenan in the capsules was less than the average daily dietary intake. Relapses were defined by a rise of two or more points on the Simple Clinical Colitis Activity Index and the need for enhanced ulcerative colitis treatment. Over the course of a year, participants were monitored every two weeks via phone calls.
In the research results, it was found that out of twelve patients, those who ingested carrageenan capsules had a higher relapse rate. Notably, none of those who took the placebo experienced a relapse. The group exposed to carrageenan exhibited increased levels of inflammation indicators - the Interleukin-6 and the fecal calprotectin biomarkers - by the end of their participation in the study. There was no such increase observed in the placebo group.
Acupuncture and moxibustion therapy show greater effectiveness than oral sulphasalazine in treating inflammatory bowel diseases.
2013 Evidence-Based Complementary and Alternative Medicine Acupuncture and Moxibustion for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Ji, J., Lu, Y., Liu, H., et al.
Systematic Review Autoimmune Diseases Inflammatory Bowel Disease Inflammatory Bowel Diseases
For the methodology, seven significant databases, both domestic and international, were meticulously searched to accumulate and examine randomized controlled trials (RCTs). These trials specifically compared acupuncture and moxibustion as the main intervention to pharmacotherapy in treating Inflammatory bowel diseases (IBD). In total, 43 RCTs were incorporated and examined, 10 of which distinctly compared oral sulphasalazine with acupuncture or/and moxibustion treatments.
In regards to the results received, the study found that acupuncture and moxibustion therapy displayed superior results when compared with oral sulphasalazine. This conclusion is drawn from the meta-analysis of the 10 trials focusing specifically on these treatments. Even though the systemic review presented several limitations and a definitive conclusion wasn't reached, it still laid groundwork for the potential effectiveness of acupuncture and moxibustion therapy in managing Inflammatory bowel diseases.